Nemaura Pharma Limited (Pharma) and NDM Technologies Limited (NDM) are entities controlled by the Company's majority shareholder Dewan FH Chowdhury.

From inception, Pharma invoiced DDL and TCL for research and development services. In addition, certain operating expenses of DDL and TCL were incurred and paid by Pharma and NDM. In accordance with the United States Securities and Exchange Commission (SEC) Staff Accounting Bulletin 55, these financial statements reflect all costs associated with the operations of DDL and TCL. While certain costs incurred by Pharma and NDM are directly attributable to DDL and TCL, other costs were shared between the organizations. In situations where the costs were shared, expense has been allocated between Pharma and NDM and DDL and TCL using a fixed percentage allocation. Management believes the methodologies used are reasonable and that the costs allocated are not materially different from what they would have been had Pharma and NDM been unaffiliated entities. DDL and TCL advanced Pharma certain amounts to cover a portion of the costs. The remaining amounts were contributed to the Company in the form of contributed services.

Following is a summary of activity between the Company and Pharma and NDM for the three months ended  June 30, 2015 (unaudited) and the year ended March 31, 2015:

Advances to Pharma as of June 30, 2015 consist of amounts advanced in connection with the Company's planned clinical trials. The remaining advances  of  approximately $70,000 are expected to be fully expensed in the second quarter of fiscal 2015 through the next stage of clinical trials.

At June 30, 2015, the net balance due from Pharma is comprised of the remaining clinical trials advances of approximately $70,000, net of approximately $56,000 payable to Pharma.